Evidence map›Paper›PMID 41857122›Full record

ArticleNature chemistry2026

Degradation of G-quadruplex-binding proteins in chromatin using G4-ligand-based proteolysis-targeting chimeras.

Zixuan Wang, Xuan He, Xiaoyun Zhang, Jochen Spiegel, Sean M Flynn, Shankar Balasubramanian

Abstract read
In one paragraph

Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. JACS Au · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zixuan WangYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.ORCID 0009-0002-6554-1230
Xuan HeYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.ORCID 0009-0004-4589-675X
Xiaoyun ZhangYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.ORCID 0000-0002-4132-3573
Jochen SpiegelYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7641-1066
Sean M FlynnCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
Shankar BalasubramanianYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK. sb10031@cam.ac.uk.ORCID 0000-0002-0281-5815

Funding

Cancer Research UK (CRUK) C9681/A29214Cancer Research UK (CRUK) SEBINT-2024/100003Wellcome Trust (Wellcome) 209441/Z/17/Z
6 · The paper itself

Abstract

Targeted protein degradation can intervene with the function of disease-related proteins, but most current approaches rely on direct ligand engagement of a protein target, limiting their applicability to proteins that are difficult to bind selectively. Here we present a conceptually unique approach to degrade proteins associated with DNA G-quadruplex (G4) secondary structures in a chromatin context. G4s are non-canonical nucleic acid structures that form at regulatory regions of transcriptionally active genes in open chromatin, and are abundant in cancer states. Although many proteins recognize or regulate G4 structures, selectively targeting G4-binding proteins in their native chromatin environment is challenging. Our bifunctional molecules are proteolysis-targeting chimeras that bind naturally occurring G4s, recruit E3 ubiquitin ligases and degrade G4-specific transcription factors and chromatin remodellers such as FUS, SMARCA4 and ATRX. These proteins are important therapeutic targets that play crucial roles in transcription regulation and DNA repair. Our approach has the potential to be exploited in a therapeutic strategy to target diseases characterized by aberrant G4 activity, such as cancers.

Indexed as

ChromatinG-QuadruplexesProteolysis Targeting ChimeraDNA HelicasesHumansLigandsNuclear ProteinsProteolysisTranscription FactorsChromatinDNA HelicasesLigandsNuclear ProteinsProteolysis Targeting ChimeraTranscription Factors

Identifiers

PMID41857122
PMCPMC13236602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.